A retrospective survey of the last 3 months of life in patients carrying glioblastoma: Clinical treatments and profiles

Rivoirard,Romain; Vallard,Alexis; Boutet,Claire; Falk,Alexander  Tuan; Garin,Clemence; Adjabi,Anissa; Hoarau,Delphine; Forest,Fabien; Fotso,Marie‑Jeannette; Rancoule,Chloe; Magné,Nicolas

doi:10.3892/mco.2017.1479

A retrospective survey of the last 3 months of life in patients carrying glioblastoma: Clinical treatments and profiles

Authors:
- Romain Rivoirard
- Alexis Vallard
- Claire Boutet
- Alexander Tuan Falk
- Clemence Garin
- Anissa Adjabi
- Delphine Hoarau
- Fabien Forest
- Marie‑Jeannette Fotso
- Chloe Rancoule
- Nicolas Magné
View Affiliations

Affiliations: Department of Medical Oncology, Lucien Neuwirth Institute of Cancerology, 42270 Saint Priest en Jarez, France, Department of Radiotherapy, Lucien Neuwirth Institute of Cancerology, 42270 Saint Priest en Jarez, France, Department of Morphological and Functional Imaging, St. Etienne North Hospital, 42270 Saint Priest en Jarez, France, Departement of Radiation Oncology, Centre Antoine Lacassagne, 06100 Nice, France, Anatomopathology Laboratory, CHU Saint Etienne, 42270 Saint Priest en Jarez, France, Department of Neurosurgery, CHU Saint Etienne, 42270 Saint Priest en Jarez, France
Published online on: November 2, 2017 https://doi.org/10.3892/mco.2017.1479
Pages: 115-120

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma is one of the most common types of primary brain tumor. In situations of local recurrence, physicians can suggest either specific palliative anticancer treatments (SPAT; surgery, chemotherapy, radiotherapy) or best supportive care (BSC). The objective of the present study was to identify clinical factors that may have influenced the continuation or cessation of SPAT during the final 3 months of life in patients with glioblastoma. In the present retrospective single‑center study, all records of patients treated for glioblastoma, who succumbed to the disease between June 2006 and February 2014, were assessed. All selected patients were divided into two groups, according to treatments received during the last 3 months of life: The SPAT and BSC groups. A total of 148 patients were included: 81 patients in the SPAT group (group A) and 67 patients in the BSC group (group B). A performance status equal to 0 was observed for 17.3% of patients in group A vs. 6% in group B. Following progression, chemotherapy was administered in 39.5% of cases in group A vs. 20.9% of cases in group B (P=0.0149). The mean number of lines of chemotherapy administered in group A was equal to 1.44±0.77 as compared with 1.06±0.67 in group B (P=0.0017). SPAT are utilized frequently among patients approaching mortality due to a glioblastoma. Certain factors, including the utilization of novel chemotherapy after the first progression or number of lines of chemotherapy previously administered, may have influenced physicians' decisions whether to continue with the SPAT or not.

View Figures

View References

1	Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the united states in 2008–2012. Neuro Oncol. 17 Suppl 4:iv1–iv62. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P, Bauchet F, Kerr C, Fabbro M, Figarella-Branger D, et al: French brain tumor database: General results on 40,000 cases, main current applications and future prospects. Neurochirurgie. 58:4–13. 2012.(In French). View Article : Google Scholar : PubMed/NCBI
3	Baldi I, Huchet A, Bauchet L and Loiseau H: Epidemiology of glioblastoma. Neurochirurgie. 56:433–440. 2010.(In French). View Article : Google Scholar : PubMed/NCBI
4	Chakrabarti I, Cockburn M, Cozen W, Wang YP and Preston-Martin S: A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer. 104:2798–2806. 2005. View Article : Google Scholar : PubMed/NCBI
5	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
6	Hart MG, Grant R, Garside R, Rogers G, Somerville M and Stein K: Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 16:CD0072942011.
7	Lonjon N, Bauchet L, Duffau H, Fabbro-Peray P, Segnarbieux F, Paquis P and Lonjon M: Second surgery for glioblastoma. A 4-year retrospective study conducted in both the Montpellier and Nice Departments of Neurosurgery. A literature review. Neurochirurgie. 56:36–42. 2010.
8	Addeo R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V, Genovese M, et al: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol. 102:417–424. 2011. View Article : Google Scholar : PubMed/NCBI
9	Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH and Wilson CB: Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg. 63:218–223. 1985. View Article : Google Scholar : PubMed/NCBI
10	Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL and Elfring GL: Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 97(9 Suppl): S2381–S2386. 2003. View Article : Google Scholar
11	Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, et al: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A north american brain tumor consortium study. Neuro-Oncol. 8:189–193. 2006. View Article : Google Scholar : PubMed/NCBI
12	Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, et al: Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 27:1262–1267. 2009. View Article : Google Scholar : PubMed/NCBI
13	Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009. View Article : Google Scholar : PubMed/NCBI
14	Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 25:4722–4729. 2007. View Article : Google Scholar : PubMed/NCBI
15	Combs SE, Thilmann C, Edler L, Debus J and Schulz-Ertner D: Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution. J Clin Oncol. 23:8863–8869. 2005. View Article : Google Scholar : PubMed/NCBI
16	Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, et al: Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas. J Clin Oncol. 28:3048–3053. 2010. View Article : Google Scholar : PubMed/NCBI
17	Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B and Ryu S: Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival. J Neurooncol. 92:185–191. 2009. View Article : Google Scholar : PubMed/NCBI
18	Derouesne C, Poitreneau J, Hugonot L, Kalafat M, Dubois B and Laurent B: Mini-Mental State Examination: A useful method for the evaluation of the cognitive status of patients by the clinician. Presse Med. 28:1141–1148. 1999.PubMed/NCBI
19	Viel E, Chaigneau L, Fanton E, Kalbacher E, Thiery-Vuillemnin A, Villanueva C, Dobi E, Curtit E, Almotlak H, Aubry R and Pivot X: Specific anticancer treatments in the last 3 months of life: A French experience. Support Care Cancer. 21:405–412. 2013. View Article : Google Scholar : PubMed/NCBI
20	Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD and Weeks JC: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 22:315–321. 2004. View Article : Google Scholar : PubMed/NCBI
21	Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC and Ayanian JZ: Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol. 26:3860–3866. 2008. View Article : Google Scholar : PubMed/NCBI
22	Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O and Ash AS: Chemotherapy use among medicare beneficiaries at the end of life. Ann Intern Med. 138:639–643. 2003. View Article : Google Scholar : PubMed/NCBI
23	Barnato AE, Herndon MB, Anthony DL, Gallagher PM, Skinner JS, Bynum JP and Fisher ES: Are regional variations in end-of-life care intensity explained by patient preferences? A Study of the US Medicare Population. Med Care. 45:386–393. 2007. View Article : Google Scholar : PubMed/NCBI
24	Voogt E, van der Heide A, Rietjens JA, van Leeuwen AF, Visser AP, van der Rijt CC and van der Maas PJ: Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol. 23:2012–2019. 2005. View Article : Google Scholar : PubMed/NCBI